The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World

The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine p...

Descripción completa

Detalles Bibliográficos
Autor principal: Jhaveri, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985932/
https://www.ncbi.nlm.nih.gov/pubmed/33832783
http://dx.doi.org/10.1016/j.clinthera.2021.03.007
_version_ 1783668344859131904
author Jhaveri, Ravi
author_facet Jhaveri, Ravi
author_sort Jhaveri, Ravi
collection PubMed
description The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther. 2021;43:702–710) © 2021 Elsevier HS Journals, Inc.
format Online
Article
Text
id pubmed-7985932
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-79859322021-03-23 The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World Jhaveri, Ravi Clin Ther Commentary The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther. 2021;43:702–710) © 2021 Elsevier HS Journals, Inc. Elsevier Inc. 2021-04 2021-03-23 /pmc/articles/PMC7985932/ /pubmed/33832783 http://dx.doi.org/10.1016/j.clinthera.2021.03.007 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Jhaveri, Ravi
The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World
title The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World
title_full The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World
title_fullStr The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World
title_full_unstemmed The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World
title_short The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World
title_sort next set of covid-19 vaccines: leveraging new development platforms to increase access for more people around the world
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985932/
https://www.ncbi.nlm.nih.gov/pubmed/33832783
http://dx.doi.org/10.1016/j.clinthera.2021.03.007
work_keys_str_mv AT jhaveriravi thenextsetofcovid19vaccinesleveragingnewdevelopmentplatformstoincreaseaccessformorepeoplearoundtheworld
AT jhaveriravi nextsetofcovid19vaccinesleveragingnewdevelopmentplatformstoincreaseaccessformorepeoplearoundtheworld

Ejemplares similares